Teva to Host Generic Medicines Business Overview on September 9, 2016
29 Août 2016 - 5:50PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today
that it will host a conference call and live webcast along with a
slide presentation on Friday, September 9, 2016 at 8:00 a.m. ET to
communicate an overview of the future prospects of Teva Generics
business following the close of the Actavis generics deal. The
presentation will focus on strategy, commercial, portfolio and
R&D capabilities and will include an overview of specific
pipeline opportunities in 2017 and beyond.
In order to participate, please dial the following numbers (at
least 10 minutes before the scheduled start time): United States
1-866-254-0808; Canada 1-866-607-2172 or International +44(0) 1452
541003; passcode: 67432981. For a list of other international
toll-free numbers, click here.
A live webcast of the call will also be available on Teva's
website at: www.ir.tevapharm.com Please log in at least 10 minutes
prior to the conference call in order to download the applicable
audio software.
Following the conclusion of the call, a replay of the webcast
will be available within 24 hours on the Company's website. The
replay can also be accessed until October 7, 2016, 9:00 a.m. ET by
calling United States 1-866-247-4222; Canada 1-866-878-9237 or
International +44(0) 1452550000; passcode: 67432981.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients
every day. Headquartered in Israel, Teva is the world’s largest
generic medicines producer, leveraging its portfolio of more than
1,000 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2015 amounted to $19.7
billion. For more information, visit www.tevapharm.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160829005728/en/
Teva Pharmaceutical Industries Ltd.IR:Kevin C. Mannix,
215-591-8912 (United States)Ran Meir, 215-591-3033 (United
States)Tomer Amitai, 972-(3)-926-7656 (Israel)PR:Iris
Beck Codner, 972-(3)-926-7246 (Israel)Denise Bradley,
215-591-8974 (United States)
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024